Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 2, 2011, Pages 217-224

  Mino, Y ^a   Naito, T ^a   Otsuka, A ^a   Takayama, T ^a   Ozono, S ^a   Kagawa, Y ^b   Kawakami, J ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

cyclosporine; free concentration; kidney transplantation; mycophenolic acid; mycophenolic acid glucuronide

Indexed keywords

ALBUMIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DRUG METABOLITE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SERUM ALBUMIN; TACROLIMUS; TIME FACTORS;

EID: 79952268625     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01168.x     Document Type: Article

References (32)

1. Jeong H, Kaplan B, (2007) Therapeutic monitoring of mycophenolate mofetil. Clinical Journal of the American Society of Nephrology, 2, 184-191.
2. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P, (2004) Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. American Journal of Transplantation, 4, 1079-1083. (Pubitemid 38868597)
3. Shipkova M, Armstrong VW, Wieland E, et al. (1999) Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. British Journal of Pharmacology, 126, 1075-1082. (Pubitemid 29123740)
4. Mourad M, Malaise J, Chaib Eddour D, et al. (2001) Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clinical Chemistry, 47, 1241-1248. (Pubitemid 32579112)
5. Pillans PI, Rigby RJ, Kubler P, et al. (2001) A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clinical Biochemistry, 34, 77-81. (Pubitemid 32178510)
6. Cattaneo D, Gaspari F, Ferrari S, et al. (2001) Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clinical Transplantation, 15, 402-409. (Pubitemid 33099961)
7. Weber LT, Shipkova M, Armstrong VW, et al. (2002) The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. Journal of the American Society of Nephrology, 13, 759-768. (Pubitemid 34183943)
8. Mudge DW, Atcheson BA, Taylor PJ, Pillans PI, Johnson DW, (2004) Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Therapeutic Drug Monitoring, 26, 453-455. (Pubitemid 38989666)
9. Bullingham RE, Nicholls AJ, Kamm BR, (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clinical Pharmacokinetics, 34, 429-455. (Pubitemid 28273453)
10. Nowak I, Shaw LM, (1995) Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clinical Chemistry, 41, 1011-1017.
11. Johnson AG, Rigby RJ, Taylor PJ, et al. (1999) The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant patients. Clinical Pharmacology and Therapeutics, 66, 492-500.
12. Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR, (2007) The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation, 84, 362-373. (Pubitemid 47258325)
13. Srinivas TR, Meier-Kriesche HU, Kaplan B, (2005) Pharmacokinetic principles of immunosuppressive drugs. American Journal of Transplantation, 5, 207-217. (Pubitemid 40179507)
14. Magee CC, Pascual M, (2004) Update in renal transplantation. Archives of Internal Medicine, 164, 1373-1388. (Pubitemid 38937848)
15. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J, (1999) Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Therapeutic Drug Monitoring, 21, 35-43. (Pubitemid 29077452)
16. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T, (2004) Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. The Journal of Pharmacology and Experimental Therapeutics, 309, 1029-1035. (Pubitemid 38669688)
17. Hesselink DA, van Hest RM, Mathot RA, et al. (2005) Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. American Journal of Transplantation, 5, 987-994. (Pubitemid 40571246)
18. Cremers S, Schoemaker R, Scholten E, et al. (2005) Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. British Journal of Clinical Pharmacology, 60, 249-256. (Pubitemid 41224132)
19. Mino Y, Naito T, Matsushita T, et al. (2008) Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. Therapeutic Drug Monitoring, 30, 656-661.
20. Heller T, van Gelder T, Budde K, et al. (2007) Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. American Journal of Transplantation, 7, 1822-1831. (Pubitemid 46905448)
21. Naito T, Mino Y, Otsuka A, et al. (2009) Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients. The Journal of Clinical Pharmacology, 49, 710-718.
22. Mino Y, Naito T, Otsuka A, et al. (2009) Cyclosporine concentration-dependent increase in concentration ratio of mycophenolic acid acyl and phenol glucuronides to mycophenolic acid in stable kidney transplant recipients. Clinical Biochemistry, 42, 595-601.
23. Patel CG, Harmon M, Gohh RY, Akhlaghi F, (2007) Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus. Therapeutic Drug Monitoring, 29, 87-95. (Pubitemid 46279881)
24. Beckebaum S, Armstrong VW, Cicinnati VR, et al. (2009) Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil. Therapeutic Drug Monitoring, 31, 205-210.
25. Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH, (2008) Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and acyl glucuronide metabolites in stable thoracic transplant recipients. Therapeutic Drug Monitoring, 30, 282-291.
26. Grinyõ JM, Ekberg H, Mamelok RD, et al. (2009) The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation, 24, 2269-2276.
27. Cussonneau X, Bolon-Larger M, Prunet-Spano C, Bastien O, Boulieu R, (2007) Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 852, 674-678. (Pubitemid 46839213)
28. Atcheson BA, Taylor PJ, Mudge DW, et al. (2005) Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. British Journal of Clinical Pharmacology, 59, 271-280. (Pubitemid 40388081)
29. Jiao Z, Zhong JY, Zhang M, Shi XJ, Yu YQ, Lu WY, (2007) Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. European Journal of Clinical Pharmacology, 63, 27-37. (Pubitemid 46025470)
30. Imai E, Horio M, Nitta K, et al. (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clinical and Experimental Nephrology, 11, 41-50. (Pubitemid 46474965)
31. Mino Y, Naito T, Matsushita T, Kagawa Y, Kawakami J, (2008) Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 46, 603-608.
32. Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. (2004) Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Therapeutic Drug Monitoring, 26, 284-286. (Pubitemid 38703015)